Data subsets to be shared today in plenary oral presentations at the 2023 Society for Neuro-Oncology Annual MeetingBRISBANE, Calif., Nov. 17, 2023 Day One Biopharmaceuticals , a clinical-stage.
BioMimetix JV, LLC, a clinical-stage biotechnology company developing metalloporphyrins, a novel drug class for the treatment of cancer patients, today announced the presentation of encouraging data from its Phase 2 study of lead candidate, BMX-001,.
The glioblastoma multiforme market is expected to witness a significant positive shift owing to the positive outcomes of the several products during the developmental stage by key players such